Common TRAEs were grade 1-2 (injection site reactions, fever, headache, and vomiting), and combination therapy had no new or severe toxicities.<h4>Conclusions</h4>EGF/EGFR vaccines may improve survival in EGFR-driven solid tumors, particularly NSCLC and GBM. This evidence concerns the gene EGF and glioblastoma.